In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B round for Phase Bioscience raises $25mm; closed at $48.4mm

Executive Summary

Phase Bioscience (developing cost-effective production technology to purify protein and peptide therapeutics, improving their efficacy and side-effect profiles) has closed its Series B venture round. Johnson & Johnson Development Corp. Hatteras Venture Partners, and Fletcher Spaght Ventures brought in the initial $4mm. The company will use the proceeds to continue developing purification and drug delivery technologies acquired from Duke University. In connection with the financing, a member of J&J Development Corp. will take a seat on Phase Bioscience's board.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies